Cardiovascular Center, The First Hospital of Jilin University, Changchun, China.
Department of Pathology, Qianfoshan Hospital Affiliated to Shandong University, Jinan, China.
Cell Death Dis. 2017 Aug 24;8(8):e3018. doi: 10.1038/cddis.2017.410.
Doxorubicin (DOX) is a highly effective antineoplastic anthracycline drug; however, the adverse effect of the cardiotoxicity has limited its widespread application. Fibroblast growth factor 21 (FGF21), as a well-known regulator of glucose and lipid metabolism, was recently shown to exert cardioprotective effects. The aim of this study was to investigate the possible protective effects of FGF21 against DOX-induced cardiomyopathy. We preliminarily established DOX-induced cardiotoxicity models in H9c2 cells, adult mouse cardiomyocytes, and 129S1/SyImJ mice, which clearly showed cardiac dysfunction and myocardial collagen accumulation accompanying by inflammatory, oxidative stress, and apoptotic damage. Treatment with FGF21 obviously attenuated the DOX-induced cardiac dysfunction and pathological changes. Its effective anti-inflammatory activity was revealed by downregulation of inflammatory factors (tumor necrosis factor-α and interleukin-6) via the IKK/IκBα/nuclear factor-κB pathway. The anti-oxidative stress activity of FGF21 was achieved via reduced generation of reactive oxygen species through regulation of nuclear transcription factor erythroid 2-related factor 2 transcription. Its anti-apoptotic activity was shown by reductions in the number of TUNEL-positive cells and DNA fragments along with a decreased ratio of Bax/Bcl-2 expression. In a further mechanistic study, FGF21 enhanced sirtuin 1 (SIRT1) binding to liver kinase B1 (LKB1) and then decreased LKB1 acetylation, subsequently inducing AMP-activated protein kinase (AMPK) activation, which improved the cardiac inflammation, oxidative stress, and apoptosis. These alterations were significantly prohibited by SIRT1 RNAi. The present work demonstrates for the first time that FGF21 obviously prevented DOX-induced cardiotoxicity via the suppression of oxidative stress, inflammation, and apoptosis through the SIRT1/LKB1/AMPK signaling pathway.
阿霉素(DOX)是一种高效的抗肿瘤蒽环类药物;然而,其心脏毒性的不良反应限制了它的广泛应用。成纤维细胞生长因子 21(FGF21)作为一种众所周知的葡萄糖和脂质代谢调节剂,最近被证明具有心脏保护作用。本研究旨在探讨 FGF21 对 DOX 诱导的心肌病的可能保护作用。我们初步建立了 H9c2 细胞、成年小鼠心肌细胞和 129S1/SyImJ 小鼠的 DOX 诱导的心脏毒性模型,这些模型清楚地显示出心脏功能障碍和心肌胶原积累,同时伴有炎症、氧化应激和细胞凋亡损伤。FGF21 的治疗明显减轻了 DOX 诱导的心脏功能障碍和病理变化。通过 IKK/IκBα/核因子-κB 通路下调炎症因子(肿瘤坏死因子-α和白细胞介素-6),显示出其有效的抗炎活性。FGF21 的抗氧化应激活性是通过调节核转录因子红细胞 2 相关因子 2 的转录来减少活性氧的产生来实现的。通过减少 TUNEL 阳性细胞和 DNA 片段的数量以及 Bax/Bcl-2 表达比值的降低,显示出其抗细胞凋亡活性。在进一步的机制研究中,FGF21 增强了 SIRT1 与肝激酶 B1(LKB1)的结合,然后降低了 LKB1 的乙酰化,随后诱导 AMP 激活蛋白激酶(AMPK)的激活,从而改善了心脏的炎症、氧化应激和细胞凋亡。这些变化被 SIRT1 RNAi 显著阻止。本研究首次证明,FGF21 通过抑制氧化应激、炎症和细胞凋亡,通过 SIRT1/LKB1/AMPK 信号通路明显预防 DOX 诱导的心脏毒性。